<SEC-DOCUMENT>0001213900-22-011484.txt : 20220310
<SEC-HEADER>0001213900-22-011484.hdr.sgml : 20220310
<ACCEPTANCE-DATETIME>20220310101632
ACCESSION NUMBER:		0001213900-22-011484
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220310
FILED AS OF DATE:		20220310
DATE AS OF CHANGE:		20220310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SciSparc Ltd.
		CENTRAL INDEX KEY:			0001611746
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38041
		FILM NUMBER:		22727837

	BUSINESS ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916
		BUSINESS PHONE:		972-3-6103100

	MAIL ADDRESS:	
		STREET 1:		20 RAUL WALLENBERG STREET, TOWER A
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6971916

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SciSparc Ltd./ADR
		DATE OF NAME CHANGE:	20210129

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Therapix Biosciences Ltd.
		DATE OF NAME CHANGE:	20140624
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea156691-6k_scisparc.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report of Foreign Private Issuer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Rule 13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of March 2022 (Report No. 2)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission file number: 001-38041</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCISPARC LTD.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>20 Raul Wallenberg Street, Tower A,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Tel Aviv 6971916 Israel</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F &#9746;&nbsp;&nbsp; Form 40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;____</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 10, 2022, SciSparc
Ltd. (the &ldquo;Company&rdquo;) issued a press release titled &ldquo;SciSparc Launches New JV Targeting Discovery of Potential Drugs
for Cancers and Infectious Diseases&rdquo;. A copy of this press release is furnished herewith as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The first, second and fourth paragraphs and the section titled &ldquo;Forward-Looking
Statements&rdquo; in the press release attached as Exhibit 99.1 are incorporated by reference into the registration statements on Form
F-3 (File No.&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390018007936/ff32018_therapixbio.htm">333-225745</A>&nbsp;and
File No.&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390019016523/ff32019_therapixbio.htm">333-233417</A>) and
on Form S-8 (File No.&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1611746/000121390018008005/fs82018_therapixbiosciences.htm">333-225773</A>)
of the Company, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted,
to the extent not superseded by documents or reports subsequently filed or furnished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 90%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea156691ex99-1_scisparc.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release titled: &ldquo;SciSparc Launches New JV Targeting Discovery of Potential Drugs for Cancers and Infectious Diseases&rdquo;.</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SIGNATURES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>SciSparc Ltd.</U></B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 10, 2022</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Oz Adler</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oz Adler</FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer &amp; <BR>
Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea156691ex99-1_scisparc.htm
<DESCRIPTION>PRESS RELEASE TITLED: "SCISPARC LAUNCHES NEW JV TARGETING DISCOVERY OF POTENTIAL DRUGS FOR CANCERS AND INFECTIOUS DISEASES"
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SciSparc Launches New JV Targeting Discovery of Potential Drugs for Cancers and Infectious Diseases</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Research builds on studies with support from global experts in
the field of small molecule drugs and gene editing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TEL AVIV, Israel, March 10, 2022 /PRNewswire/ -- SciSparc Ltd. (NASDAQ:
SPRC) (the &ldquo;Company&rdquo; or &ldquo;SciSparc&rdquo;), a specialty, clinical-stage pharmaceutical company focusing on the development
of therapies to treat disorders of the central nervous system, today announced the intended formation of a joint venture (&ldquo;JV&rdquo;)
to focus on the discovery and development of potential drugs for cancers and other life-threatening conditions. Under the terms of the
JV, to promote this intention, SciSparc will establish a new drug discovery company, MitoCareX Bio Ltd., an Israeli corporation (&ldquo;MitoCareX
Bio&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="ex99-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The JV will focus on investigating mitochondrial carriers, transport
proteins crucial for cell viability. Because of mitochondrial carriers&rsquo; significant role in transporting necessary metabolites for cell
functioning across the inner mitochondrial membranes, the Company believes various life-threatening conditions, such as cancers and rare
mitochondrial diseases, might be treated by regulating the function of mitochondrial carriers. In humans, the mitochondrial carrier family
(<I>Solute Carrier Family 25, SLC25</I>) consists of 53 members and is the largest solute transporter family.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;This is an exciting opportunity to potentially further expand
our pipeline into multiple new indications targeting large unmet medical needs,&rdquo; stated Oz Adler, Chief Executive Officer and Chief
Financial Officer of SciSparc. &ldquo;MitoCareX Bio intends to employ computationally-based drug discovery capabilities, leveraging vast
research experience and specific knowledge in the field, to discover and potentially develop a pipeline that may include small molecules
targeting the proteins of interest in various life-threatening conditions.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To form the JV, SciSparc will establish a new drug discovery company,
MitoCareX Bio Ltd. (&ldquo;MitoCareX Bio&rdquo;). Based on pre-determined milestones, SciSparc will invest up to $1.7 million, for up to
50.01 percent ownership, in MitoCareX Bio over the next two years and according to a number of milestones agreed upon in the agreement.
MitoCareX Bio&rsquo;s innovative research will partly build upon successful proof-of-concept experiments performed in the UK. Professor Ciro
Leonardo Pierri (University of Bari, Italy), a global expert in the field of mitochondrial carrier proteins, has indicated to the Company
that he intends to support the program as a consultant to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About SciSparc (NASDAQ: SPRC):</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SciSparc Ltd. is a specialty clinical-stage pharmaceutical company
led by an experienced team of senior executives and scientists. Our focus is on creating and enhancing a portfolio of technologies and
assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs
based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 for the treatment of Tourette syndrome, for the treatment of obstructive
sleep apnea and Alzheimer&rsquo;s disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum
disorder and status epilepticus. Learn more at&nbsp;https://scisparc.com/.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains forward-looking statements within the meaning
of the &ldquo;safe harbor&rdquo; provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For
example, SciSparc is using forward-looking statements when it discusses establishment of a joint venture company to focus on discovery,
research and development of potential drugs for cancers and other life-threatening conditions and in investing in new innovative research
opportunities to potentially further expand the Company&rsquo;s pipeline into multiple new indications targeting medical needs. Historic results
of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest
identical or even similar conclusions. Because such statements deal with future events and are based on SciSparc&rsquo;s current expectations,
they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially
from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this
press release are subject to other risks and uncertainties, including those discussed under the heading &ldquo;Risk Factors&rdquo; in SciSparc&rsquo;s
Annual Report on Form 20-F filed with the SEC on March 30, 2021, and in subsequent filings with the U.S. Securities and Exchange Commission.
Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements,
which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Logo -&nbsp;https://mma.prnewswire.com/media/1434686/SciSparc_Ltd_Logo.jpg</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>IR@scisparc.com&nbsp;<BR>
Tel: +972-3-6167055</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $W 3<# 2(  A$! Q$!_\0
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M&#>-TTR[M?&2+NMY?+MYF.990.I)'!7I@]37?4 %%%% !1110 4444 %%%%
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M&'OV Y'>O1J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBN6^(/B+4O"W@^\U;2]/%[/#C(8\1J>KD=2!Z4 6?&
M'B_3/!>@R:KJ3DJ#LBA3[\K]E'^/:O(T\>_%SQ4IO_#OA]+73CS$6B4[A_O.
M1N_ 56M=<M/C'\0?"D%RF+6RLGN+VU/W3,#R/<'"_@:^@T141410J*,*JC
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M/Q5 +*<\"\A!,3'_ &EZK^H^E>T6EY;W]M'<VD\4\$@RDD3!E8>Q% $]%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 9'B'PSH_BG3S9:Q8Q7,7\)889#ZJW
M4&OGOQM\ ]6T@R7GAQVU.S&3]G;B=![=F_#GVKZ;HH ^!)H9;>9X9HWCD0X9
M'4@J?0@UT?A'Q]X@\%70DTJ\/D$YDM9?FB?\.Q]QS7U3XR^&WA[QK"QO[417
MF,)>0 +(OU_O#V-?-GCKX4:_X*9[AH_MNEY^6\@7A1_MCJO\O>@#Z!\!_%O0
M_&JI:LPL-6QS:RMPY_V&_B^G6O017P%&[Q2+)&[(ZG*LIP0?4&O??A?\;G+P
MZ'XLGR#A(-1;J#V63_XK\_6@#Z HI%8,H((((R".]+0 4444 %%%% !1110
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MJG"J/7D9/X>M?0] !1110 4444 %%%% !1110 444R:1887E8$JBEB ,G H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBL[7=:LO#NC76JZA*([:V0NQ[G
MT ]R>* //OC7XW?PYX<31].E8:OJG[M/+/S1Q]"PQW/W1^/I77^!=/U?3/!V
MG6VN7LMWJ(CW2O(<E<\A,]\#C->2?#;1[WXC^/+OQ_KL1^QV\NVRB;[I8?=
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M+)IT][)=7$C>;-EB41CU5!V'\SS78444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M6/K_ (IT3PQ:&YUC48+5,<*S?._LJCDUX[JWQ>\2^,[U]'^'ND3@-\K7LB N
M!Z_W4'N>: /=EFC:5XED1I$P60,,KGID=JDKS7X9_#;4O"5W=:SK.LS7>J7J
M;9XE<M'USDD\LP]>*]*H *,444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445C^*KS5;#PQ?W>B6
MRW.I11[H(64MO.1Q@=>,T ;&:@NKVUL83-=W$5O$.2\KA0/Q->&[/CGXDX9H
MM(B;K@I$0/U:I;;X!ZGJLPN/%?BVXNF)R4B+.?\ OIS_ $H ]P@N(KJ".>"1
M)89%#(Z'(8'H0:DK.T+1[?P_HEGI-HTK6]K&(XS*VYL>YK1H XGQ7\+M \9>
M(;35M6$[-;Q>6T,;[5E&<C<>O'/3%=1I>CZ=HEDMGI=E!:6Z](X4"C\?4^YJ
M]10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
